MHRP began a new Ebola vaccine study last week at its site in Abuja, Nigeria in collaboration with the Nigerian Ministries of Defence and Health.
The vaccine used in the study (RV429) is the monovalent chimpanzee adenovirus Type 3 (ChAd3) candidate developed at the NIAID and being developed by GlaxoSmithKline (GSK), the study sponsor. First vaccinations began on 21 August.
Since 2005, MHRP’s program in Nigeria—called the Walter Reed Program-Nigeria—has been working closely with the Nigerian Ministries of Defence and Health to enhance HIV prevention, care and treatment through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) in Africa’s most populous nation. MHRP has also been building a sustainable research infrastructure in Nigeria for future HIV vaccine trials.
This is the first MHRP/WRAIR vaccine study to be conducted in Nigeria and the WRAIR’s fourth Ebola vaccine study to date.
